olfactory receptor family 51 subfamily A member 9 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR51A9P profile across patient tissues and cancer cell-line models. OR51A9P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LAML. Among the 18 cancer types available for tumor–normal comparison, OR51A9P is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, OR51A9P RNA expression shows 6,661 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LAML, KIRC, and STAD as cancer lineages where OR51A9P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51A9P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51A9P survival associations across molecular data types. OR51A9P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51A9P RNA expression–survival associations across cancer types. High OR51A9P expression shows unfavorable associations in LAML, CHOL, SARC, ACC, TGCT and SKCM. The LAML Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .019). Together, the overview and detailed table identify LAML as the clearest survival context for OR51A9P RNA expression.
This table summarizes OR51A9P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR51A9P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51A9P shows higher tumor expression in KIRC, PRAD and BRCA. The KIRC box plot shows higher OR51A9P RNA expression in tumor versus normal tissue (log2 FC = +0.075, t-test p < 0.001).
This table shows molecular features associated with OR51A9P in patient tissues and cancer cell lines. In patient samples, OR51A9P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
